Virtus Biotech Clinical Trials ETF BBC Open Virtus Biotech Clinical Trials ETF in new tab
Weights
Sector Weights
Country Weights
United States
Canada
United Kingdom
Netherlands
Ireland
Switzerland
Germany
Singapore
Virtus Biotech Clinical Trials ETF Analysis (BBC)
Investment Objective: Virtus Biotech Clinical Trials ETF is an investment vehicle focused on the Financial Services sector in US. It is currently trading at 43.54 USD.
Portfolio Composition:
The fund is heavily weighted towards
the Healthcare sector (100%)
and markets in
United States (90%),
Canada (2%),
United Kingdom (2%)
.
For a full breakdown of all holdings, see the "Weights" card above.
Income: This appears to be an accumulating fund (dividends are reinvested) or focuses purely on capital growth.
Investor FAQ
Does Virtus Biotech Clinical Trials ETF pay a dividend?
No, it does not currently pay a dividend.
What asset class is Virtus Biotech Clinical Trials ETF?
Virtus Biotech Clinical Trials ETF is classified as a ETF. You can compare it against its peer in the "Related Symbols" list.
Fund Strategy
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
Historical Dividends
| Year | Total Dividends |
|---|---|
| 2026 | 1.91 USD |
| Dec. 29, 2026 (estimated) | 1.9071 |
| 2025 | 0.66 USD |
| Dec. 29, 2025 | 0.6554 |
| 2024 | 0.24 USD |
| Dec. 27, 2024 | 0.2395 |
| 2023 | 0.08 USD |
| Dec. 29, 2023 | 0.0823 |
| 2017 | 0.30 USD |
| Dec. 27, 2017 | 0.3000 |
| 2015 | 0.15 USD |
| Dec. 29, 2015 | 0.1500 |
Yearly aggregated dividends
Dividends
|
Virtus Biotech Clinical Trials ETF
Dec 29, 2025 Paid
Dividend
0.65544 USD |
Historical Split Corporate Actions
Explore Premium Features
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion